目的:研究结果支持了西班牙sc疮呈上升趋势的假设。人们还担心可能会出现对治疗的抵抗力以及非典型表现的增加。这项研究的目的是描述西班牙皮肤科医生看到的sc疮患者的人口统计学和临床概况,为了确定可能出现的非典型形式的sc疮,并探讨治疗失败的频率和相关危险因素。
方法:我们进行了一项观察,横截面,使用西班牙皮肤病与性病学会(AEDV)创建的CLINI-AEDVp平台,对2023年4月和5月前瞻性收集的数据进行多中心研究。
结果:在研究期间,来自西班牙15个自治区的31家医院的皮肤科医生记录了186例活动性sc疮(女性占51%)。诊断确定性水平为A,诊断需要根据国际控制of病联盟共识标准的B或C。总的来说,92%的患者患有典型的sc疮,而66%的患者已经在当前发作中接受了杀痂剂治疗。在接受治疗的患者中,只有36%的人接受并完成了适当的治疗(包括所有家庭成员同时接受治疗),50%的人没有收到明确的书面建议.
结论:在所研究的大部分sc疮病例中,病人已经接受了治疗。在这些情况下,我们观察到几个可弥补的缺陷,这些缺陷可以解释其中一些治疗失败的原因.纠正这些缺陷应导致更好地控制sc疮,并改善对当前可用sc杀的实际有效性的评估。
BACKGROUND: Several studies support the hypothesis that scabies is on the rise in Spain. There are also concerns about the possible development of resistance to treatment and an increase in atypical presentations. The aims of this study were to describe the demographic and clinical characteristics of patients with scabies seen by dermatologists in Spain, to identify the possible emergence of atypical forms of scabies, and to explore the frequency of treatment failures and associated risk factors.
METHODS: We conducted an observational, cross-sectional, multicenter study of data collected prospectively in April and May 2023 using the CLINI-AEDVp platform created by the Spanish Academy of Dermatology and Venereology (AEDV).
RESULTS: Participating dermatologists from 31 hospitals in 15 of Spain\'s autonomous communities recorded 186 cases of active scabies (51% in women) during the study period. A diagnostic certainty level of A, B or C as per the International Alliance for the Control of Scabies Consensus Criteria was required for diagnosis. Overall, 92% of patients had clinical features of classic scabies and 66% had already been treated with a scabicide for the current episode. Of the treated patients, only 36% had received and completed adequate treatment (including the simultaneous treatment of all household members) and 50% had not received clear written recommendations.
CONCLUSIONS: In a high proportion of scabies cases, the patient has already received treatment. In those cases, we observe several remediable shortcomings that could explain why some of these treatments fail. Remedying these deficiencies should lead to better control of scabies and an improved assessment of the actual effectiveness of currently available scabicides.